Myelin oligodendrocyte glycoprotein antibody disease: incidence, prevalence, outcome prediction and immunopathology

Project: Research project

Project Details


PROJECT NARRATIVE This research proposal has public health relevance because myelin oligodendrocyte glycoprotein antibody disease (MOGAD) can result in blindness, wheelchair dependence or coma and the fundamental epidemiology knowledge we provide will determine its global burden, guide resource allocation, provoke research into risk factors by identifying regional variation and help clinical trial readiness by allowing better prediction of recruitment. Moreover, the findings from this proposal will provide information that physicians can immediately incorporate into clinical practice to guide diagnostic and therapeutic decision making in MOGAD patients. The proposed research is relevant to the NIH mission because it will improve outcomes, reduce harm, and lead to better understanding of MOGAD pathogenesis which is a potential first step towards developing novel treatments in this disease.
Effective start/end date12/1/1911/30/22


  • National Institute of Neurological Disorders and Stroke: $313,116.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.